Immix Biopharma Employees

As of December 31, 2024, Immix Biopharma had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees increased by 4 or 23.53% compared to the previous year.

Employees

Change (1Y)

Growth (1Y)

23.53%

Revenue / Employee

n/a

Profits / Employee

-$1,401,839

Market Cap

455.90M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	21	4	23.53%
Dec 31, 2023	17	6	54.55%
Dec 31, 2022	11	9	450.00%
Dec 31, 2021	2	-	-

Related Stocks

Company Name	Employees
MiMedx Group	808
Valneva SE	674
Lyell Immunopharma	300
4D Molecular Therapeutics	196
Verastem	102
enGene Therapeutics	82
Upstream Bio	75
Fulcrum Therapeutics	55

Employee Rankings

IMMX News

19 days ago - Immix Biopharma to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
4 weeks ago - Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones - GlobeNewsWire
2 months ago - Immix Biopharma to Participate in Upcoming Investor Conferences - GlobeNewsWire
3 months ago - Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 - GlobeNewsWire
5 months ago - Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
5 months ago - Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
5 months ago - At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - GlobeNewsWire
5 months ago - Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch - GlobeNewsWire

More News